- Home
- SPPP vs PLRX Comparison
SPPP vs PLRX Comparison
Compare SPPP & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPP
- PLRX
- Stock Information
- Founded
- SPPP 2011
- PLRX 2015
- Country
- SPPP Canada
- PLRX United States
- Employees
- SPPP N/A
- PLRX N/A
- Industry
- SPPP
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SPPP
- PLRX Health Care
- Exchange
- SPPP NYSE
- PLRX Nasdaq
- Market Cap
- SPPP 140.9M
- PLRX 165.5M
- IPO Year
- SPPP N/A
- PLRX 2020
- Fundamental
- Price
- SPPP $9.76
- PLRX $1.47
- Analyst Decision
- SPPP
- PLRX Hold
- Analyst Count
- SPPP 0
- PLRX 10
- Target Price
- SPPP N/A
- PLRX $9.79
- AVG Volume (30 Days)
- SPPP 183.3K
- PLRX 3.4M
- Earning Date
- SPPP 01-01-0001
- PLRX 03-03-2025
- Dividend Yield
- SPPP N/A
- PLRX N/A
- EPS Growth
- SPPP N/A
- PLRX N/A
- EPS
- SPPP N/A
- PLRX N/A
- Revenue
- SPPP N/A
- PLRX N/A
- Revenue This Year
- SPPP N/A
- PLRX N/A
- Revenue Next Year
- SPPP N/A
- PLRX $46.66
- P/E Ratio
- SPPP N/A
- PLRX N/A
- Revenue Growth
- SPPP N/A
- PLRX N/A
- 52 Week Low
- SPPP $8.55
- PLRX $1.26
- 52 Week High
- SPPP $11.39
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- SPPP 55.55
- PLRX 26.84
- Support Level
- SPPP $9.57
- PLRX $1.42
- Resistance Level
- SPPP $9.73
- PLRX $1.78
- Average True Range (ATR)
- SPPP 0.12
- PLRX 0.13
- MACD
- SPPP 0.00
- PLRX 0.26
- Stochastic Oscillator
- SPPP 66.67
- PLRX 14.08
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.